Keep the finding close to the health claim
These four names turn up around health claims. We’ve kept the finding that matters for each, with the missing answers and safety concerns right beside it.
BPC-157 has a large gap in human evidence
BPC-157 has no FDA-approved use. FDA’s evidence review found only a handful of small human studies. The published injection reports had no comparison groups, so they cannot show that BPC-157 caused the improvements people reported.
That’s the gap behind the healing claims: an encouraging report isn’t a dependable answer about an injury. A comparison helps us judge what might have changed without the treatment.
FDA also raises concerns about immune reactions to BPC-157 given by injection or through the nose, possibly worsened by impurities or peptide clumps. This is a risk assessment, not a measured rate of reactions. The small studies don’t settle long-term safety.
A GHK-Cu cream cannot speak for an injection
GHK-Cu is a short peptide attached to copper. GHK itself occurs naturally in human fluids. Those biological facts explain some of the interest, but don’t show what a treatment will do.
The route is the useful detail to keep hold of. A review of skin-cream research found a shortage of studies in people. Even a positive result with a cream would not establish a benefit from injecting it.
No GHK-Cu medicine is FDA-approved. For injections, FDA highlights possible immune reactions involving clumps or impurities, with little human safety information available. A familiar cosmetic ingredient still needs its own evidence when the route changes.
Sermorelin’s old approvals have limits
Sermorelin tells the pituitary—the little gland just below the brain—to send out growth hormone. It isn’t growth hormone itself. Its former approvals covered a hormone-response test and growth failure in children with growth hormone deficiency.
Those approvals were withdrawn in 2009. FDA’s later finding concerned why the products left sale: safety and effectiveness were not the reasons. Today’s compounded preparations are not FDA-approved.
In one small study of older men, growth hormone rose without a change in body fat or muscle. That doesn’t establish a general benefit for ageing. Older research reported flushing and injection-site pain, mostly in specialist studies involving children; it cannot settle long-term adult safety.
A higher NAD+ reading is not a health result
NAD+ is a coenzyme, a helper in cell energy reactions, rather than a peptide. Studies of precursors, ingredients the body uses to make NAD+, can show higher blood levels. A review of human ageing research found limited evidence that those changes bring health benefits.
A higher reading is not the same as feeling better or living longer. And a study of something swallowed cannot establish the benefit of NAD+ given through a vein.
A small report looking back at infusion tolerability described stomach symptoms, a faster heart rate and chest pressure. It doesn’t tell us how often these happen for all users. Across these examples, a useful care question is “What improved for people, and what is still unknown?”